2019
Prioritization of Therapeutic Targets and Trial Design in Cirrhotic Portal Hypertension
Abraldes JG, Trebicka J, Chalasani N, D’Amico G, Rockey DC, Shah VH, Bosch J, Garcia‐Tsao G. Prioritization of Therapeutic Targets and Trial Design in Cirrhotic Portal Hypertension. Hepatology 2019, 69: 1287-1299. PMID: 30318607, PMCID: PMC11090176, DOI: 10.1002/hep.30314.Peer-Reviewed Original ResearchConceptsNonalcoholic fatty liver diseasePortal pressurePortal hypertensionLiver diseaseCardiac output leadsCause of cirrhosisCirrhotic portal hypertensionChronic liver diseaseFatty liver diseasePortal venous inflowIntrahepatic vascular resistanceRisk of decompensationEarly clinical studiesCirrhosis decompensationSplanchnic vasodilationVascular resistancePharmacological therapyEtiological treatmentVenous inflowCirrhosis resultsSuch therapyClinical trialsBest therapyClinical studiesCirrhosis
2011
Management: Cirrhotic Portal Hypertension
Lim J, Garcia-Tsao G. Management: Cirrhotic Portal Hypertension. 2011, 165-181. DOI: 10.1007/978-1-4419-8327-5_11.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsPortal hypertensionVariceal hemorrhageAcute variceal hemorrhageCirrhotic portal hypertensionBetter risk stratificationNovel pharmacotherapeutic agentsGastroesophageal varicesPortal pressureRisk stratificationMain complicationsNoninvasive markerPharmacotherapeutic agentsIndividualized careHypertensionVaricesHemorrhageSignificant mortalityCirrhosisSignificant improvementProphylaxisComplicationsPatientsRecurrenceMortality